Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma.
METHODS
A 7-year-old Golden Retriever was examined because of anorexia, lethargy, vomiting, and gradual weight loss.


RESULTS
Splenomegaly, pancytopenia, high serum calcium concentration, and high alkaline phosphatase activity were detected. Magnetic resonance imaging revealed an enlarged mesenteric lymph node and increased signals from the bone marrow of the ilium and vertebral bodies. Histologic examination and immunophenotyping of biopsy specimens confirmed a stage V (b) T-cell malignant lymphoma.


RESULTS
Clinical remission was attained by use of 2 chemotherapy cycles, followed by an allogeneic hematopoietic cell transplant performed at 18 weeks after diagnosis. A donor was identified by molecular dog leukocyte antigen typing methods. The patient was conditioned with 2 fractions of 4 Gy total body irradiation delivered 3 hours apart at 7 cGy/min, followed by an IV infusion of recombinant canine granulocyte colony-stimulating factor mobilized leukapheresis product and postgrafting immunosuppression with cyclosporine. Chimerism analyses revealed full donor engraftment that has been maintained for at least 58 weeks after transplant. Remission has been confirmed by normal results of serum thymidine kinase assays and the absence of peripheral blood clonal T-cell receptor gene rearrangements.


CONCLUSIONS
Systemic chemotherapy induces remissions; however, most dogs succumb to disease recurrence because of multidrug resistance. Outcome of allogeneic hematopoietic cell transplantation in dogs can be excellent because of improved donor-recipient selection by use of molecular dog leukocyte antigen typing, compared with early attempts, and better prevention of graft versus host disease, better supportive care, and substitution of peripheral blood mononuclear cells for bone marrow.
Lupu
Marilena
M
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.
Sullivan
Edmund W
EW
Westfall
Theresa E
TE
Little
Marie-Térèse
MT
Weigler
Benjamin J
BJ
Moore
Peter F
PF
Stroup
Patrice A
PA
Zellmer
Eustacia
E
Kuhr
Christian
C
Storb
Rainer
R
D000818:Animals; D016572:Cyclosporine / Q000494:pharmacology; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000662:veterinary*; D006649:Histocompatibility Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D007165:Immunosuppression Therapy / Q000379:methods / Q000662:veterinary*; D016399:Lymphoma, T-Cell / Q000628:therapy / Q000662:veterinary*; D008297:Male; D018183:Transplantation Chimera; D014184:Transplantation, Homologous / Q000662:veterinary; D016896:Treatment Outcome; D014916:Whole-Body Irradiation / Q000662:veterinary
D006649:Histocompatibility Antigens; D016179:Granulocyte Colony-Stimulating Factor; D016572:Cyclosporine